FORM 3
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
  RIOUX PATRICE
2. Date of Event Requiring Statement (Month/Day/Year)
01/08/2018
3. Issuer Name and Ticker or Trading Symbol
Monopar Therapeutics [NONE]
(Last)
(First)
(Middle)
C/O MONOPAR THERAPEUTICS INC, 1000 SKOKIE BLVD., SUITE 350
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner
_____ Officer (give title below) __X__ Other (specify below)
Acting Chief Medical Officer
5. If Amendment, Date Original Filed(Month/Day/Year)
(Street)

WILMETTE, IL 60091
6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)
2. Amount of Securities Beneficially Owned
(Instr. 4)
3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)
4. Nature of Indirect Beneficial Ownership
(Instr. 5)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. SEC 1473 (7-02)
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 4)
2. Date Exercisable and Expiration Date
(Month/Day/Year)
3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)
4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)
6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Stock options   (1)   (1) Common stock 7,000 $ 0.001 D  
Stock options   (2)   (2) Common stock 32,004 $ 6 D  

Reporting Owners

Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
RIOUX PATRICE
C/O MONOPAR THERAPEUTICS INC
1000 SKOKIE BLVD., SUITE 350
WILMETTE, IL 60091
      Acting Chief Medical Officer

Signatures

/s/ Kim R. Tsuchimoto, Attorney-in-fact 01/08/2018
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) Reflects the issuance of options to purchase up to 7,000 shares of common stock granted to Dr. Rioux on December 15, 2016 for his services as acting chief medical officer to Monopar Therapeutics. The options are fully vested as of June 15, 2017. The options each expire on December 14, 2026.
(2) Reflects the issuance of options to purchase up to 32,004 shares of common stock granted to Dr. Rioux on January 1, 2018 for his services as acting chief medical officer to Monopar Therapeutics. The options vest 12,000 shares on the grant date and and 1,667 options on the first of each month thereafter. The options each expire on December 31, 2027.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.